Exactech (NSDQ:EXAC) said today it sold the entirety of its dental biologics business to Salvin Dental Specialties, through its Salvin Regenerative subsidiary. Financial terms and other details of the deal were not disclosed.
Salvin Dental develops, manufactures and markets implant dentistry regenerative biomaterials and surgical instrumentation, Exactech said.
“While it has been a pleasure to provide Exactech’s biologic innovations to the dental market for more than 10 years, we have made the strategic decision to focus more exclusively on our core orthopaedic business. We have enjoyed a long-standing distribution relationship with Salvin, which gives us confidence that they will take good care of our dental customers in their pursuit of improving patient care,” Exactech spine and biologics GM Bruce Thompson said in a press release.
Exactech’s dental biologics biz includes its Oralife and Optecure dental bone graft. Optecure is designed for reconstruction and augmentation of deficient maxillary and mandibular alveolar ridges and dental intraossesous defects, according to the company.
The purchase will add depth to Salvin Dental’s product line and increase the company’s manufacturing capabilities, CEO Bob Salvin said in prepared remarks.
In October, Exactech said it launched its Opterak revision knee system and that the system has been successfully implanted in its 1st set of patients.
The revision knee system is composed of proprietary net compression molded polyethylene and is indicated for use in skeletally mature patients undergoing surgery for total knee replacements due to osteoarthritis, osteonecrosis, rheumatoid arthritis and post-traumatic degenerative problems, as well as to revise previously failed reconstructions, Exactech said.
The company hopes to see full market availability in the U.S. for the device in 2016.
